TACROLIMUS
DrugBank ID: db00864
DrugCentral: tacrolimus
Synonymous :anhydrous tacrolimus | tacrolimus | tacrolimus anhydrous | tacrolimus, anhydrous
Drug Sentece Context
Table 1. Analysis of context sentence of tacrolimus gene in 44 abstracts.
| pmid | sentence |
|---|---|
| 32256705 | Using Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 blockade, mycophenolate, tacrolimus, anti-CD20 and CTLA4-Ig. 89 studies were included. […] Low-dose prednisolone and tacrolimus may have beneficial impacts on COVID-19. |
| 32279418 | Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. |
| 32337859 | However, the unexpected fluctuations in tacrolimus trough levels needed to be managed because of drug-to-drug interaction. |
| 32351040 | Nine patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. |
| 32362392 | Of these, 21.3% of recipients had pre-existing lymphopenia, and 87.2% of recipients had a therapeutic concentration of tacrolimus (5-12 ng/ml). |
| 32400931 | His maintenance immunosuppressive regime was consisted of tacrolimus (TAC, 1mg twice a day, orally), mycophenolate mofetil (MMF, 0.5g twice a day, orally) and prednisone (Pred, 5mg daily, orally) triple combination. |
| 32471001 | Tacrolimus was withdrawn in 70%. |
| 32513289 | Current use of CYP 3A4 or P-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. |
| 32529737 | Two therapeutic strategies were compared: Group 1) minimization of calcineurin inhibitors (N=6); Group 2) cyclosporine-based therapy (N=23), with 15 patients switched from tacrolimus. |
| 32541471 | He was treated with modified immunosuppressants (unchanged dose of tacrolimus and oral corticosteroids while discontinuing mycophenolate mofetil (MMF)), antibiotics, interferon α-2b inhalation and traditional Chinese medicine. |
| 32583620 | All five patients were on immunosuppressive therapy with mycophenolate mofetil (MMF) and tacrolimus and three that were transplanted within the prior two months were additionally on prednisone. |
| 32585765 | A 58-year-old 2 years post kidney transplant recipient, with maintenance immunosuppression of tacrolimus, mycophenolate mofetil (MMF) and prednisolone, presented with acute diarrhea which followed by fever on day 12. […] Patient has been transferred to our hospital on day 2 of admission which tacrolimus together with MMF were discontinued. […] Drug interaction between tacrolimus and anti-viral treatment lead to severely high level of tacrolimus which caused reversible acute kidney injury (AKI) after supportive treatment. |
| 32627319 | In the overall population, dyspnea was associated with the risk of ARDS and age older than 60 years and dyspnea were associated with the risk of death with only a trend toward an increased risk of death for patients on tacrolimus. |
| 32640747 | Finally, we made a critical analysis of a number of substances, not yet utilized, but potentially useful in SARS-CoV-2 patients, such as IFN lambda, TNF blockers, ulinastatin, siponimod, tacrolimus, mesenchymal stem cells, inhibitors of mononuclear macrophage recruitment, IL-1 family antagonists, JAK-2 or STAT-3 inhibitors. |
| 32646657 | It is also important to pay attention to possible drug interactions, especially in the case of tacrolimus, with some of the treatments with antiviral effect given in the context of COVID 19 (lopinavir/ritonavir, azithromycin). |
| 32678882 | In the hospitalized group, tacrolimus dosage was reduced in 46% of patients and mycophenolate mofetil (MMF) therapy was stopped in 61% of patients. […] None of the ambulatory patients had tacrolimus reduction or discontinuation of MMF. |
| 32690572 | The patient was admitted for 1 day; immunosuppressive therapy with tacrolimus and low-dose prednisolone was continued; and the patient recovered successfully without the use of antiviral agents or oxygen therapy. |
| 32703929 | Kidney transplant patients encountered COVID-19 were maintained on tacrolimus (Tac, 92%), mycophenolate mofetil (MMF, 78.8%), and prednisone (Pred, 77%) and were manage by holding MMF in 79.1% of patients and holding Tac in 34.4% of patients. |
| 32835277 | Despite continued corticosteroid and tacrolimus therapy, he remained aviremic. |
| 32862472 | Mycophenolate mofetil was discontinued in all cases upon admission, whereas baseline steroids were maintained and tacrolimus dose was reduced. |
| 32892322 | Three months posttransplant a recurrence of podocytopathy was successfully managed by plasma exchange, ivIG, and a conversion from tacrolimus to belatacept (initial proteinuria > 6 g/l decreased to 169 mg/l). |
| 32979013 | Patient received standard prednisone and tacrolimus-based immunosuppression without induction therapy following transplant. |
| 33032841 | Paradoxically, the patient with more risks of developing a severe disease, a 64-year-old woman, 2-years liver transplant recipient under treatment with tacrolimus, presented a similar outcome compared to the two other members of the family. […] The present clinical observation raises the question about the possible beneficial effect of tacrolimus in patients with COVID-19. […] Indeed, tacrolimus (FK-506) have an inhibitory effect on human coronaviruses by: 1) an antiviral effect by binding to the FK-506-binding proteins (FKBP) with a subsequent inhibition of their peptidyl-prolyl cis/trans isomerase (PPIase) activity, which seems to be important for the coronavirus life cycle; and 2) regulating the immune response by the inhibition of the activity of the nuclear factor of activated T-cells (NFAT) required for immunosuppression. […] The present observation states that liver recipients’ patients with COVID-19 may not have worse outcomes when compared with other patients that have COVID-19 risk factors and puts in evidence the two mechanisms related to tacrolimus. |
| 33039144 | Immunosuppressive therapy with tacrolimus and mycophenolate mofetil was continued throughout the course of infection. |
| 33041077 | The large proportion of infected individuals were minorities (Hispanic 65.9%, black 14.6%), on prednisone, tacrolimus, and mycophenolate mofetil (95.1%, 87.8%, and 87.8%, respectively), and had excellent allograft function (median 1.25 mg/dL). |
| 33043603 | Initial CT values from upper respiratory tract samples were significantly higher in patients on tacrolimus, but were not associated with admission severity nor highest clinical acuity. |
| 33048372 | We compared three groups based on immunosuppression regimen 7-12 months posttransplant: 1) tacrolimus (Tac)+mycophenolic acid (MPA)+prednisone (Pred) (referent group, 77.7%); 2) Tac+MPA+Pred+HCQ (16.5%); or 3) other immunosuppression+HCQ (5.7%). |
| 33089648 | There was a strong interaction between tacrolimus and LPV/r in all cases. |
| 33098713 | In the Danish population, we examined whether patients treated with thiopurines, methotrexate, systemic corticosteroids, anti-tumour necrosis factor (TNF)-α agents, anti-interleukin therapeutic agents, selective immunosuppressive agents and cyclosporine/tacrolimus had an increased risk of hospitalization for COVID- 19, compared to the background population. […] Exposed patients constituted those exposed to thiopurines (n = 5484), methotrexate (n = 17 977), systemic corticosteroids (n = 55 868), anti-TNF-α agents (n = 17 857), anti-interleukin therapeutic agents (n = 3744), selective immunosuppressive agents (n = 3026) and cyclosporine/tacrolimus (n = 1143) in a period of 12 months prior to 1 March 2020 (estimated time of outbreak in Denmark). […] The adjusted odds ratios of hospitalization in patients treated with corticosteroids and cyclosporine/tacrolimus were 1.64 (95% confidence interval [CI] 1.35 to 2.00) and 4.75 (95% CI 1.96 to 11.49), respectively. […] Patients treated with systemic corticosteroids and cyclosporine/tacrolimus had a significantly increased risk of being hospitalized for COVID-19. |
| 33100064 | Her mycophenolate mofetil was stopped after admission, and tacrolimus was discontinued 10 days later. […] A diuretic was administered, and prednisone was gradually reduced along with tacrolimus. |
| 33130946 | We found statistically significant increases in RSV for colchicine, hydroxychloroquine, tocilizumab (and its brand name-Actemra), and anakinra, and statistically significant decreases among brand names of immunosuppressive agents (i.e., mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, cyclosporine) during both the initial- and short-term COVID-19 periods as compared to overlapping periods of the preceding 3 years. |
| 33183020 | With antiviral treatment and temporary discontinuation of tacrolimus immunosuppression, he had complete clinical symptoms relieve on day 24. |
| 33185367 | Tacrolimus/m-TOR inhibitors were reduced by 50% and all antimetabolites were discontinued. |
| 33196625 | Compared with the RT-PCR+ cohort, patients with serological-proven infection alone were more likely to be receiving tacrolimus monotherapy, P < 0.01, and less likely to have a diagnosis of diabetes, P = 0.012. |
| 33307029 | After multivariable Cox regression analysis, age >70 (HR, 4.16; 95% CI, 1.78-9.73) had a negative effect and tacrolimus (TAC) use (HR, 0.55; 95% CI, 0.31-0.99) had a positive independent effect on survival. |
| 33312897 | The tacrolimus blood level was determined and the elevation in creatinine was found to be related to an interaction between tacrolimus and azithromycin. |
| 33355203 | Immunosuppressive medications used include: glucocorticoids (76%), mycophenolate mofetil (MMF) (54%), tacrolimus/ciclosporine A (58%), rituximab/ofatumumab (11%). 78% required no respiratory support during COVID-19 illness, 5% required bi-level positive airway pressure or ventilation. |
| 33410884 | Of these, 108 (5%) were classified as immunosuppressed before COVID-19, primarily with prednisone (>7.5 mg/day), tacrolimus, or mycophenolate mofetil. |
| 33421213 | Maintenance immunosuppression included tacrolimus (84.2%), mycophenolate (89.5%), and corticosteroids (81.6%) in the majority of patients. |
| 33439508 | Patients were managed with standard immunosuppression protocols, including lymphocyte depleting induction and trough-guided tacrolimus. |
| 33451758 | Since the transplant, these 2 patients have received triple maintenance immunosuppressive therapy with oral tacrolimus, mycophenolate mofetil (MMF), and prednisone, and they have been regularly followed up at our hospital. […] The tacrolimus trough level was between 10 and 12 ng/mL. […] After the diagnosis of COVID-19, MMF was stopped and the tacrolimus dose was reduced so that blood level was between 4 and 6 ng/mL. |
| 33495742 | Our working hypothesis is that methylprednisolone pulses and tacrolimus may be an effective and safety drug combination for treating severe COVID-19 patients. and analysis: TACROVID is a randomized, open-label, single-center, phase II trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) versus SoC alone, in patients at advanced stage of COVID-19 disease with lung injury and systemic hyperinflammatory response. […] Methylprednisolone and tacrolimus might be beneficial to treat those COVID-19 patients progressing into severe pulmonary failure and systemic hyperinflammatory syndrome. […] The rationale for its use is the fast effect of methylprednisolone pulses and the ability of tacrolimus to inhibit both the CoV-2 replication and the secondary cytokine storm. |
| 33504483 | Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. |
| 33573820 | Tacrolimus or sirolimus levels were >10 ng/mL in 6 out of 9 KTR (67%). |